Regentis Biomaterials Ltd. (NYSE American: RGNT) is positioning its Gelrin C hydrogel as a practical regenerative medicine solution for cartilage damage that could help address the substantial clinical and economic burden associated with knee osteoarthritis (OA). Gelrin C is a cell-free, off-the-shelf hydrogel administered in a single 10-minute procedure, designed to support cartilage regeneration while avoiding the multiple surgeries, specialized laboratory processing and higher costs associated with some cell-based therapies.
With approximately 470,000 knee cartilage repair procedures performed annually in the U.S., representing an estimated $3 billion market, the company believes Gelrin C could offer a more scalable approach that fits existing surgical workflows and addresses cartilage defects before they progress to costly OA. The economic impact of knee OA is significant: estimates indicate the annual U.S. economic burden ranges from approximately $5.7 billion to $15 billion, with lifetime costs for affected patients potentially exceeding $140,000.
As Regentis advances Gelrin C toward commercialization, its single-stage design, proprietary hydrogel technology and clinical data could position the company to benefit from growing demand for regenerative treatments that preserve joint health and potentially delay or prevent more expensive degenerative disease. The company’s Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone.
Regentis’ lead product, GelrinC, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. The product aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is currently available.
For more information about Regentis Biomaterials, visit the company’s newsroom at https://ibn.fm/RGNT.
